Trial Profile
Single-arm, open-label, prospective study for apatinib combined with AI inhibitors in patients with advanced HER2-negative, HR-positive breast cancer
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 25 Oct 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Aromatase inhibitors
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 25 Oct 2018 New trial record